[Reaferon treatment in acute HBsAG-positive viral hepatitis].

Abstract

Clinical, biochemical and serological examinations of 412 patients with acute HBsAg-positive virus hepatitis were conducted to assess therapeutic efficacy of Soviet recombinant alpha 2-interferon (reaferon). There were 309 cases of acute virus hepatitis B, 103 of delta infection (71--coinfection, 32--superinfection). The study and control groups were assigned randomly. Reaferon i.m. administration started on jaundice day 1-5 and lasted for 10-11 days. The treatment proved effective in acute hepatitis B running a moderately severe and severe course up to the development of acute hepatic encephalopathy. In delta infection reaferon produced response in coinfection only. In fulminant hepatitis the treatment was uneffective.

• Authors: I P Gorbarets, E S Ketiladze, N A Farber, N P Bugaeva, D M Braginskiĭ
• Journal: Klinicheskaia meditsina (Klin Med (Mosk)) Vol. 68 Issue 3 Pg. 65-8 (Mar 1990) ISSN: 0023-2149 [Print] Russia (Federation)
• Vernacular Title: Lechenie reaferonom ostrogo HBsAg-polozhitel'nogo virusnogo gepatita.
• PMID: 2370758 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Hepatitis B Surface Antigens
• Interferon Type I
• Recombinant Proteins

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Drug Evaluation
• Hepatitis B (complications, immunology, therapy)
• Hepatitis B Surface Antigens (analysis)
• Hepatitis D (complications, therapy)
• Humans
• Interferon Type I (therapeutic use)
• Middle Aged
• Recombinant Proteins